Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Delamanid Resistance: Update and Clinical Management

5 Jun 2020

Abstract excerpt

Delamanid, a-first-in-class bicyclic nitroimidazole, was recently approved for multidrug-resistant tuberculosis treatment. Pitted against the hope for improving treatment outcomes is the threat of the rapid resistance emergence. This review provides information on the mechanisms of action, resistance emergence, and drug susceptibility testing (DST) for delamanid. Delamanid resistance has already been reported in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Mycobacterium research and diagnosis
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32521000
DOI: 10.1093/cid/ciaa755

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 26 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Delamanid Resistance: Update and Clinical ManagementPMID 32521000Read ↗

Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practiceSemantic proximity Read ↗

Spontaneous Mutational Patterns and Novel Mutations for Delamanid Resistance in Mycobacterium tuberculosis.Semantic proximity Read ↗

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.Semantic proximity Read ↗

Delamanid and bedaquiline resistance patterns in Mycobacterium tuberculosis in Iran: A cross-sectional analysisSemantic proximity Read ↗

Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients.Semantic proximity Read ↗

Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis.Semantic proximity Read ↗

Spontaneous mutations to delamanid and pretomanid resistance in Mycobacterium tuberculosis: SNPs confer high-level resistance.Semantic proximity Read ↗

Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in ChinaSemantic proximity Read ↗

Natural Polymorphisms in <i>Mycobacterium tuberculosis</i> Conferring Resistance to Delamanid in Drug-naïve PatientsSemantic proximity Read ↗

Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.Semantic proximity Read ↗

Investigation of delamanid, bedaquiline, and linezolid resistance rates and related gene mutations in multidrug-resistant Mycobacterium tuberculosis in regional tuberculosis reference laboratories of Iran.Semantic proximity Read ↗

Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.